169 related articles for article (PubMed ID: 37733187)
21. Cost-Effectiveness Analysis of Adjuvant Endocrine Therapy With Ovarian Suppression in Premenopausal Patients With Hormone Receptor-Positive Early Breast Cancer in China.
Zhong X; Chen P; He P; Wu Y; Suo J; Zhu K; Yan X; Tian T; Yang Q; Luo T
Clin Breast Cancer; 2024 Feb; 24(2):e41-e50. PubMed ID: 37865566
[TBL] [Abstract][Full Text] [Related]
22. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.
Tevaarwerk AJ; Wang M; Zhao F; Fetting JH; Cella D; Wagner LI; Martino S; Ingle JN; Sparano JA; Solin LJ; Wood WC; Robert NJ
J Clin Oncol; 2014 Dec; 32(35):3948-58. PubMed ID: 25349302
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew A; Davidson NE
Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis.
Jiang M; Chen W; Hu Y; Chen C; Li H
Medicine (Baltimore); 2021 Aug; 100(33):e26949. PubMed ID: 34414958
[TBL] [Abstract][Full Text] [Related]
25. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
26. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
Montagna E; Cancello G; Colleoni M
Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant ovarian function suppression and cognitive function in women with breast cancer.
Phillips KA; Regan MM; Ribi K; Francis PA; Puglisi F; Bellet M; Spazzapan S; Karlsson P; Budman DR; Zaman K; Abdi EA; Domchek SM; Feng Y; Price KN; Coates AS; Gelber RD; Maruff P; Boyle F; Forbes JF; Ahles T; Fleming GF; Bernhard J
Br J Cancer; 2016 Apr; 114(9):956-64. PubMed ID: 27092785
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
29. Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.
Meattini I; Livi L; Saieva C; Franceschini D; Scotti V; Mangoni M; Loi M; Di Brina L; Zei G; Bonomo P; Greto D; Gelain E; Nori J; Sanchez LJ; Orzalesi L; Bianchi S; Biti G
Clin Breast Cancer; 2013 Aug; 13(4):247-53. PubMed ID: 23684167
[TBL] [Abstract][Full Text] [Related]
30. Breast density reduction as a predictor for prognosis in premenopausal women with estrogen receptor-positive breast cancer: an exploratory analysis of the updated ASTRRA study.
Bae SJ; Kim HJ; Kim HA; Ryu JM; Park S; Lee EG; Im SA; Jung Y; Park MH; Park KH; Kang SH; Park E; Kim SY; Lee MH; Kim LS; Lee A; Noh WC; Gwark S; Kim S; Jeong J
Int J Surg; 2024 Feb; 110(2):934-942. PubMed ID: 38000057
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis.
Azim HA; Shohdy KS; Kaldas DF; Kassem L; Azim HA
Curr Probl Cancer; 2020 Dec; 44(6):100592. PubMed ID: 32527567
[TBL] [Abstract][Full Text] [Related]
32. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer.
Kubo M
Chin Clin Oncol; 2020 Jun; 9(3):33. PubMed ID: 32527118
[TBL] [Abstract][Full Text] [Related]
34. First-line endocrine therapy for advanced breast cancer. A real-world study at a Latin American university health institution.
Walbaum B; Acevedo F; Medina L; Bravo ML; Merino T; Camus M; Dominguez F; Mondaca S; Galindo H; Nervi B; Ibañez C; Madrid J; Peña J; Koch E; Garrido M; Pinto MP; Sánchez C
Curr Med Res Opin; 2020 Jul; 36(7):1195-1199. PubMed ID: 32351137
[No Abstract] [Full Text] [Related]
35. The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress.
Kim HA; Ahn SH; Nam SJ; Park S; Ro J; Im SA; Jung YS; Yoon JH; Hur MH; Choi YJ; Lee SJ; Jeong J; Cho SH; Kim SY; Lee MH; Kim LS; Moon BI; Kim TH; Park C; Kim SJ; Jung SH; Park H; Gwak GH; Kang SH; Kim JG; Kim J; Choi SY; Lim CW; Kim D; Yoo Y; Song YJ; Kang YJ; Jung SS; Shin HJ; Lee KJ; Han SH; Lee ES; Han W; Kim HJ; Noh WC
BMC Cancer; 2016 May; 16():319. PubMed ID: 27197523
[TBL] [Abstract][Full Text] [Related]
36. Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial.
Baek SY; Noh WC; Ahn SH; Kim HA; Ryu JM; Kim SI; Lee EG; Im SA; Jung Y; Park MH; Park KH; Kang SH; Jeong J; Park E; Kim SY; Lee MH; Kim LS; Lim W; Kim S; Kim HJ
J Clin Oncol; 2023 Nov; 41(31):4864-4871. PubMed ID: 37607321
[TBL] [Abstract][Full Text] [Related]
37. Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.
Partridge AH; Niman SM; Ruggeri M; Peccatori FA; Azim HA; Colleoni M; Saura C; Shimizu C; Sætersdal AB; Kroep JR; Mailliez A; Warner E; Borges VF; Amant F; Gombos A; Kataoka A; Rousset-Jablonski C; Borstnar S; Takei J; Lee JE; Walshe JM; Borrego MR; Moore HC; Saunders C; Cardoso F; Susnjar S; Bjelic-Radisic V; Smith KL; Piccart M; Korde LA; Goldhirsch A; Gelber RD; Pagani O
Breast; 2021 Oct; 59():327-338. PubMed ID: 34390999
[TBL] [Abstract][Full Text] [Related]
38. Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial.
Kim HA; Lee JW; Nam SJ; Park BW; Im SA; Lee ES; Jung YS; Yoon JH; Kang SS; Lee SJ; Park KH; Jeong J; Cho SH; Kim SY; Kim LS; Moon BI; Lee MH; Kim TH; Park C; Jung SH; Gwak G; Kim J; Kang SH; Jin YW; Kim HJ; Han SH; Han W; Hur MH; Noh WC;
J Clin Oncol; 2020 Feb; 38(5):434-443. PubMed ID: 31518174
[TBL] [Abstract][Full Text] [Related]
39. Revisiting adjuvant ovarian suppression in premenopausal breast cancer patients.
Abbas W; Rao RR
Indian J Cancer; 2019; 56(4):293-296. PubMed ID: 31607695
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.
Ribi K; Luo W; Bernhard J; Francis PA; Burstein HJ; Ciruelos E; Bellet M; Pavesi L; Lluch A; Visini M; Parmar V; Tondini C; Kerbrat P; Perelló A; Neven P; Torres R; Lombardi D; Puglisi F; Karlsson P; Ruhstaller T; Colleoni M; Coates AS; Goldhirsch A; Price KN; Gelber RD; Regan MM; Fleming GF
J Clin Oncol; 2016 May; 34(14):1601-10. PubMed ID: 27022111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
